CERA

Science and Research

RAVEN: A Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

The purpose of this study is to evaluate the effectiveness and safety of brolucizumab in the treatment of patients with visual impairment caused by macular swelling due to central retinal vein occlusion. 

Overview

In this study, you will be assigned to receive either brolucizumab or aflibercept (the current approved treatment for macular oedema due to CRVO in Australia). Both drugs are given by an injection into your eye.

Participation in this study involves a total of 21 study visits held every 4 weeks for 80 weeks (approximately 18 months).

  • Principal Investigator
Associate Professor Sanj Wickremasinghe

Learn more

View this study at ClinicalTrials.gov

This international database listing provides more detailed information about this study.